Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05244122 · ClinicalTrials.gov registry record · NA
PROJECT 2 EXAMPLE: Feedback X Prevalence Using Dermatology Stimuli
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 1,121
- Enrollment target
NCT05244122: Completed NA study, sponsored by Brigham and Women's Hospital.
NCT05244122 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 1,121 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05244122, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,121 participants
- Enrollment target
Study Summary
Imagine that a dermatologist spends the morning seeing patients who have been referred for suspicion of skin cancer. Many of them do, in fact, have skin lesions that require treatment. For this set of patients, disease 'prevalence' would be high. Suppose that the next task is to spend the afternoon giving annual screening exams to members of the general population. Here disease prevalence will be low. Would the morning's work influence decisions about patients in the afternoon? It is known from other contexts that recent history can influence current decisions and that target prevalence has an impact on decisions. In this study, decisions were decisions about skin lesions from individuals with varying degrees of expertise, using an online, medical imaging labelling app (DiagnosUs). This allowed examination of the effects of feedback history and prevalence in a single study. Blocks of trials could be of low or high prevalence, with or without feedback. Over 300,000 individual judgements were collected. (taken from Wolfe, J. M. (2022). How one block of trials influences the next: Persistent effects of disease prevalence and feedback on decisions about images of skin lesions in a large online study. . Cognitive Research: Principles and Implications (CRPI), 7, 10. doi: https://doi.org/10.1186/s41235-022-00362-0
Primary Outcome
D' (d-prime) is defined as z-transform of the true positive rate - z-transform of false positive rate. True positive is when you say that a real melanoma is a melanoma. False positive is when you say that a nevis is a melanoma. A correction of 0.5 error is added to avoid calculation problems when z=0 or z=1. D' of zero indicates no ability to discriminate. D' \> zero indicates some ability to discriminate. The change of interest is the D' for Block 2 when it follows Block 1 compared to the D'
Interventions
- BEHAVIORAL Feedback
- BEHAVIORAL Prevalence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,121 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2021-06-27 |
| Phase | NA |
What the finished NCT05244122 record still lists
NCT05244122 is an interventional study that assigns participants to a tested intervention. Its 1,121 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which Feedback is the first listed.
NCT05244122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05244122 about?
NCT05244122 is a clinical study titled "PROJECT 2 EXAMPLE: Feedback X Prevalence Using Dermatology Stimuli". Imagine that a dermatologist spends the morning seeing patients who have been referred for suspicion of skin cancer. Many of them do, in fact, have skin lesions that require treatment. For this set of patients, disease 'prevalence' would be high. Suppose that the next task is to spend the afternoon ...
What is the current status of trial NCT05244122?
This trial is currently completed. It is a NA study. The enrollment target is 1,121 participants. The study started on 2021-06-22. Estimated completion is 2021-06-27.
What interventions are being tested in trial NCT05244122?
The interventions under investigation include: Feedback (BEHAVIORAL), Prevalence (BEHAVIORAL).
Who is sponsoring clinical trial NCT05244122?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05244122's enrollment target sits among peer trials
1,121 93rd of 2000 higher than 1,908 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI